NOSAI NOSAI
|
|
|
- なお おいもり
- 6 years ago
- Views:
Transcription
1 F NOSAI NOSAI F F NOSAI NOSAI F NOSAI NOSAI NOSAI
2 NOSAI NOSAI
3 NOSAI Computed Radiography CR X Computed Radiography System FCR PRIMA T X PORTA 380HF GT GC GS RNRTREDRN DRTDRE IP GS RE IP CR NOSAI HH mm HH χ T P ORP P P P
4 Cook and Burgi Dairy Comp 305 Valley Agricultural software Platelet rich plasma PRP GM TGF-β1 PRP GM PLGA PRP PRPml GM mg ml g PLGA PLGA PRP GM PLGA Corynebacterium Proteus PLGA PLGA PRP GM PLGA
5 HGF HGF kg HGFµg mm mmmmcm HGF HGF n n HGF P HGF S 100 HGF HGF Hepatocyte Growth Factor NOSAI
6 kg HE Azan PAS fast-myosin skeletal heavy chain MHC slow-mhc dystrophin dystrophin NOSAI VB VB CPK γ x x cm cm C4 C4
7 cm cm cm EPG EPG EPG EPG EPG EPG EPG EPG EPG NOSAI Trypanosoma theilerit. theileri T. theileri Ht ul T. theileri EPG T. theileri T. theileri T. theileri T. theileri
8 Ca P DCS kg ml C ml mg CH Ca ip ica Ca C mg dl CH mg dl ica C mm L CH mm L CH Ca ica C ip Ca Ca Ca DKK SARA ph SARA ph ph ph ph MHz ph mm mm PC ph ph PC ph SARA ph ph ph ph ph ph
9 NOSAI HBS C. perferingens A. fumigatus HBS Fisher Wilcoxon p K mmol L SID meq L ORCI K mmol L OR CI K TCO2 Na K SID K HBS SIRSHBS SIRS SIRS SIRS mm
10 PGµg PGmg EB Kaplan-Meier Log-rank PG EB PG EB NOSAI BCScm OXT ESE GLMM GLMM P AIC Rver GLMM cm P P P ESE OXT
11 cm cm p cm p cm p cm α PGF2α PG kg PG PG PG PG PG p cm PG p PG p p PG p PG PG PG PG PG PG PG
12 BCS BCS A BCS B BCS BCS cm A BCS r p BCS r p BCS p B BCS p BCS BCS BCS BCS p BCS cm BCS p BCS p BCS BCS BCS BCS BCS NOSAI Epidermal Growth Factor, EGF EGF mg EB P4 SP SP NOSAI EB mg mg EB mg Modified Program MP SP SP MP SP vs P SP MP vs P mg EB SP MP SP EGF
13 NOSAI AI CIDR CIDR P hcg CIDR hcg CIDR CIDR P nhcg n CIDR n hcg CIDR nhcg AI hcg CIDR AI CIDR hcg CIDR AI CIDR hcg CIDR P ng ml P hcg CIDR hcg CIDR CIDR hcg CIDR hcg hcg hcg CIDR CIDR hcg CIDR A B NOSAI CIDR mg n CIDR Modified Fast Back Program MFBP n n Fisher MFBP pmfbp p Modified Fast Back Program MFBP P4 P4 MFBP
14 NOSAI NOSAI OM Mycoplasma bovis M.bovis OM kg M. bovis Ht kg kgkg Ht OM OM Mycoplasma bovis : M. bovis OM TMS TMS MBFX M.bovis M.bovis M.bovis
15 Mp Mp Mp Mp A B C Mp Mp Mp A B C A Mp Mp Mp SDS-PAGE PCR PFGE BamH1 A Mycoplasma bovis M.bs M.bs M.bs B M.bs Mp M.bs M.bs M.bs C M.bs M.bovigenitalium M.bs Mp Mp NOSAI Mp Mp TS F-S F-L TS F-1F-0 M. bovis M. californicum F-L M. bovis M. bovigenitarium M. arginini M. canadense M. arginini M. canadense F-L F-L TS F-0 TS F-1 F-0 Mp Mp
16 BVDV PI PI PI BVDV RT PCR PI PI PI PI PI BVDV PI BVDV PI BVDV PI BVDV PI PI PI PI NOSAI BD BD BDV A BDV A BDV BDV ELISA WB BDV BDV BDV A BDV C F G I A BDV BDV A BDV
17 BSE BSE PrP Sc PMCA : Protein Misfolding Cyclic Amplification BSE PrP Sc PMCA PrP Sc BSE BSE BSE PMCA BSE BSE mlna-pta PMCA PMCA PrP Sc Na-PTA PMCA PrP Sc BSE PrP Sc PrP Sc Na-PTA PMCA PrP Sc BSE PrP Sc BSE PrP Sc BSE BLV BLV A B C DNA pol real-time PCR Heenemann BLV JNC ELISA AGID BLV A B C B C A BLV ELISA AGID ELISA BLV ELISA
18 BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV cm PCR BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV BLV
19 BToV RNA A B BToV A BToV BToV BCV BToV B BCV BToV BCV BToV A BToV GM GM A BToV BToV B BToV BToV BCV BCV BToV BToV IBR BRSV BVDV1 BVDV2 PI3 A B IBR RS BVDV1 A B Student-t P A B IBR BRSV BVDV1 B A IBR BVDV1 BRSV B A
20 PRRS PRRS PRRS PRRS PRRS PRRS PRRS PRRS PRRS NOSAI NOSAI NOSAI Charles River EU ml Se Sp Limulus Amebocyte Lysate LAL LAL-KCA Mann Whitney U Kruskal-Wallis ROC EU ml EU ml p Escherichia coli Klebsiella pneumoniae ROC EU ml Se Sp
21 NOSAI NOSAI NOSAI Charles River Limulus Amebocyte Lysate LAL EU ml LAL LAL-KTA LAL- KCA Mann-Whitney U ROC EU ml EU ml pse Sp EU ml EU ml pse Sp NOSAI Et EC Et EC KCZCXM TK CZ Et EC cfu ml Et EU ml Et K CZ CXM T K CZ Et β CXM CZ K KCZ T Et CZ Et K K KCZ Et K Et KCZ Et Et
22 MF S. Infantis A MF OTC OTC MF MF OTC OTC MF OTC MF MF NOSAI TZ TZ N TZ NT w w w Eimeria Em OPG O-ring Em Daily Gain DG Em OPG DG DG Tukey-Kramer t Em OPG NT w w w DG kg day NT w w w w w w p Em OPG DG vsp TZ TZ
23 Cryptosporidium parvum C.andersoni C.parvum C.ryanae C.bovis DNA 18SrRNA PCR PCR-RFLP C.bovis C.parvum C.bovis C.ryanae C.parvum C.bovis C.ryanae C.parvum C.bovis C.ryanae C.parvum PC.bovis C.bovis C.parvum C.bovis C.ryanae C.parvum C.bovis C.ryanae C.bovis C.bovis C.parvum C.bovis C.ryanae NOSAI T T T A B C D χ A B C D T ABC D A pc D B p ABCD A D B C p A B C D D A B p D A p B p p T C D A B
24 Listeria monocytogenes BVD-MD BVD BVDV BVDV BVD-MD BVD-MD BVD-MD BVD-MD mmhg mm mm
25 kg S CT CT NOSAI kg Ht Fe Zn ED1
26 NOSAI NSAIDs γ A G xxcm x x cm E.coli Staphylococcus spp VSD VSD ASD DORV VSD VSD VSD VSD Computed Tomography CT II VSD CT CT mm VSD 3D-CT 3D-CT mm VSD CT VSD VSD
27 kg E mgml mgml GOT CK HCO3 NOSAI Mannheimia varigenamv Mannheimia haemolytica complexmhc Mannheimia 16S rrna Mhc Mv Mannheimia haemolyticamh Mh Mv DHL β Mh 16S rrna Mv Mv Mv Mv
28 NOSAI A VA VA VA VA VA Pasteurella multocida Mycoplasma dispar A VA µg ml VA µg g β µg g VA µg ml VA VA β VA β A VA BHV-1 BHV-1 BHV-1 BHV-1 RS PCR BHV-1 BHV-1 BHV-1 BHV-1 BHV-1
29 Mortierella Mortierella wolfii Mw Mw DNA ITS BLAST mm µm bp BLAST MwITS Mw ITS BLAST
30 NOSAI BP ph BP BP BP BP BP t BP cm BP BP cm BP cm BP BP BP BP kg BCS BCS MPT PaO2 IgG1 BCS MPT PaO2mmHg mmhg IgG1 BCS
31 NOSAI NOSAI day day day Paired t n n Mann Whitney U Student s t day EAApNEAA EAA BCAA AAA p BCAA pgaa GKAA KAA day p EAA KAA p BCAA EAA day EAA KAA BCAA NOSAI A A cm kmkm
32 JRA P En n ROC P E P E2 P P E P E P4 P4 mm P4 PATHFAST P4 P4 PATHFAST PGF2α ml µg ml RIA PATHFAST r RIA r PATHFAST RIA PATHFAST RIA P4 RIA
33 cm U cm cm JRA JRA JRA TC H L P H vs P L vs P t P L H t P H L H P L P
34 SC SC SC SC SC cm SC SC SC cm SC SC SC cm SC SC SC YTB YTB YTB SC OCD SA Nec DJDIPPV SC SC SC OCD SA Nec DJD SC OCD SA SC OCD SA YTB
35 NOSAI HH Bone cyst OCD chip fracuture Bone cyst OCD NOSAI ALD ALD H H ALD H H mean SD screw&wire Staple Single screw mean SD mean SD T staple single screw ALD Staple Single screw ALD
36 β BMP-2 β mm mm BMP-2µgµg Control GT GT M-5 GT M-6 GT M-5 B-1 GT M-5 B-3 GT M-6 B-1 GT M-6 B-3 ControlGTM-5 M-6 B-1µg BMP -2 B-3µg BMP-2 X CT Control X CT GT M-5 B-3 GT M-6 B-3 X CT GT M-5 B-3 GT M-6 B-3 BMP-2 BMP-2 PRP β-tcp BMAC BMAC BMP-2µg mmmm mmmm mma B BMACµlC D CT A A β-tcp
37 Mobile Laryngoscope VideoMed Mobile Laryngoscope PC m DDSPEpiglottic Entrapment Mobile Laryngoscope Mobile Laryngoscope kgkgkg prosound α MHz G mmg mm ml ml
38 NOSAI X NOSAI kg
39 BTC BTC NOSAI Lawsonia intracellularis Li TP US TP mg dl Li PCR US TP US TP US
40 NOSAI kg X cm φ cm
41 CT X X EMPF MP MP EMPF EMPF EMPF EMPF MP MP PCR EMPF EMPF EMPF
42 CD20 CD3 HLA-DR S100 fascin S100 fascin HLA-DR B T
43 JRA EHV-1 H H X A H EHV-1 EHV-1 H X A EHV-1 ORF68 X gg-elisa EHV-1 Salmonella Abortusequi
NOSAI NOSAI
NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI FSFS FS FS FS Salmonella Typhimurium ST Salmonella Dublin SD SD ST ST NOSAI S. Aberdeen TMR χ S. Aberdeen O11 i
NOSAI NOSAI
C C NOSAI NOSAI NOSAI NOSAI NOSAI C C NOSAI NOSAI NOSAI NOSAI NOSAI NOSAI Computed Radiography CR X NOSAI NOSAI CR NOAI DICOM OSIRIX S S S S S S X IP S S S S X T4 Vertebral Heart Size VHS VHS VHS n WCS
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
w i6505.j
MHz 384 Mp Mycoplasma californicum Mycoplasma bovigenitalium Mp Mp / Mp PCR Mp / M. californicum M. bovigenitalium Mp Mp Mp Mp g OTC OTC 385 Mp Mp Mp M. californicum M. bovigenitalium Mp Mp / Mp M. californicum
総合薬学講座 生物統計の基礎
2013 10 22 ( ) 2013 10 22 1 / 40 p.682 1. 2. 3 2 t Mann Whitney U ). 4 χ 2. 5. 6 Dunnett Tukey. 7. 8 Kaplan Meier.. U. ( ) 2013 10 22 2 / 40 1 93 ( 20 ) 230. a t b c χ 2 d 1.0 +1.0 e, b ( ) e ( ) ( ) 2013
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
- - - - - - - - - - - - - - - - - - - - - - - Babesia gibsoni - Babesia gibsoni - Babesia gibsoni - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Mast Cell Tumor : MCT c-kit MCT F F MCT C c-kit DNA Canine DNA Ver DNA c-kit C c 1275 A G F c.2355 G A DNA F C F C c-kit MCT c-kit DNA MCT Kiel T B kg cm T T Stage a UW25 P MDR1 B L T B L Leptospira L
ッ ー ー ー() () 2.5 () () 21 1) -1 2) -2 10 m 5 7 23 6 1)2) 3) -1-2 H23.4.25 -15-20 4 75 5 1) -1 (5) (3) (3) (2) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) 1) ( 23 6 8 ) 2) 22 3)
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
gtf Wnt5a-Ror2 IL-8 in vitro Ozony Tron P. gingivalis SOD ELISA Location of main occluding areas and masticatory ability in patients with reduced occlusal support 12-Methacryloyloxydodecylpyridinium bromide
JP.qxd
Agilent 2100 1 DNA RNA Lab-on-a-Chip Agilent 2100 1999 Agilent 2100 Lab-on-a-Chip Agilent 2100 RNA DNA SDS-PAGE Agilent 2100 Agilent 2100 Agilent 2100 : (1 4 µl) 30 21 CFR Part 11 Agilent 2100 Agilent
8 1. 2. 3. 4. 5. 6. 7. 8. 1... 1 1.1.... 1 1.1.1.... 1 1.1.2.... 6 1.2.... 8 1.2.1.... 8 1.2.2....11 1.2.3.... 12 1.2.4.... 12 1.2.5.... 12 1.2.6.... 13 1.2.7.... 14 1.3.... 15 1.3.1.... 15 1.3.2....
381
P381 P386 P396 P397 P401 P423 P430 P433 P435 P437 P448 P451 P452 381 382 383 384 385 3.0mm 5.0mm 3.0mm 5.0mm SK SK3.0mm SK5.0mm 3.0mm PUR PUR3.0mm 2.0mm 2.0mm3.0mm 2.5mm 2.5mm3.0mm 3.0mm 5.0mm 3.0mm 1.8mm
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
-------------------------------------------------------------------------------------------------- 1 ----------------------------------------- 3 --------------------------------------------------------------------------------
01 H24事業報告（マハタ高品質種苗生産技術開発）
22 2013 24514 hcg500 IU/kg4554 16 Nested-PCRVNN 2426 0.5 ppm1 90.9 80.9 SAI54.2±0.2 0.5 m 3 211 5,000 95.214,286/2 6 3 57 9 9 010 031 m 2 0.1 ml 30 330 7 mm S S340 2024 6 mm25 37 1040 49X 192X 192X 1 14
DynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
128 3 II S 1, S 2 Φ 1, Φ 2 Φ 1 = { B( r) n( r)}ds S 1 Φ 2 = { B( r) n( r)}ds (3.3) S 2 S S 1 +S 2 { B( r) n( r)}ds = 0 (3.4) S 1, S 2 { B( r) n( r)}ds
127 3 II 3.1 3.1.1 Φ(t) ϕ em = dφ dt (3.1) B( r) Φ = { B( r) n( r)}ds (3.2) S S n( r) Φ 128 3 II S 1, S 2 Φ 1, Φ 2 Φ 1 = { B( r) n( r)}ds S 1 Φ 2 = { B( r) n( r)}ds (3.3) S 2 S S 1 +S 2 { B( r) n( r)}ds
untitled
ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter
NT40KSMG.ps
+ + +30. +* +, / 3 +. +,-,0 +,..* +.+.+.,.../.3 /+ +, +30. +, /- /1 0. 1* 1-11, +3 3+ 30 32 33 33 +*, +*., + +30/ +* + ++ +1 +3,/ -,- -2.*.+ 1 .-,, +30/ +,./ + /* /0 00. -+ 2/ 3, 3-3. +** - + +300 2 Watery
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
02.O...r.A..
8 300ha k (m 3 / / ) (0 2 ) 0405 135 270 2 12 0540 162 351 12 24 0810 216 486 500kg 135 459 127 1987 (m 3 / / ) 0566 2266 5947 9 18kg 0057 0425 1019 18 45 0142 0566 1358 45 675 0198 0708 2038 675 945 0283
1.2 M N M d- BBB / ChE etc ChE etc CCh BCh etc Ach ChE 2 Ach ChE PAM ChE
1 - d- etc etc d-tc ChE > < < < > > > or 1.1 1 d- < dtc Na + Na + I II ChE ChE ChE ( ) T Ca++ 1 Na + K + Na + Ach Ach Ach BTX Mg 2+ Ach CAT TTX Ach 1.2 M N M d- BBB / ChE etc ChE etc CCh BCh etc Ach ChE
iii 1 1 1 1................................ 1 2.......................... 3 3.............................. 5 4................................ 7 5................................ 9 6............................
2 1 7 - TALK ABOUT 21 μ TALK ABOUT 21 Ag As Se 2. 2. 2. Ag As Se 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 Sb Ga Te 2. Sb 2. Ga 2. Te 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 1 2 3 4
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
PII S (96)
C C R ( 1 Rvw C d m d M.F. Pllps *, P.S. Hp I q G U W C M H P C C f R 5 J 1 6 J 1 A C d w m d u w b b m C d m d T b s b s w b d m d s b s C g u T p d l v w b s d m b b v b b d s d A f b s s s T f p s s
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
untitled
PGF 17 6 1 11 1 12 1 2 21 2 22 2 23 3 1 3 1 3 2 3 3 3 4 3 5 4 6 4 2 4 1 4 2 4 3 4 4 4 5 5 3 5 1 5 2 5 5 5 5 4 5 1 5 2 5 3 6 5 6 1 6 2 6 6 6 24 7 1 7 1 7 2 7 3 7 4 8 2 8 1 8 2 8 3 9 4 9 5 9 6 9 3 9 1 9
産 地 区 4 佐 藤 綾 乃 1), 石 井 理 2) 2), 鈴 木 一 由 1) 酪 農 学 園 大 学 附 属 動 物 病 院,2) 酪 農 学 園 大 学 獣 医 生 産 動 物 医 療 学 分 野 外 科 学 CCFT CCFT 材 料 と 方 法 屈 腱 短 縮 モデル: CCFT X
日 本 獣 医 師 会 学 会 関 係 情 報 日 本 産 業 動 物 獣 医 学 会 日 本 小 動 物 獣 医 学 会 日 本 獣 医 公 衆 衛 生 学 会 日 本 獣 医 師 会 学 会 からのお 知 らせ 平 成 27 年 度 日 本 獣 医 師 会 獣 医 学 術 学 会 年 次 大 会 ( 秋 田 ) 地 区 学 会 長 賞 受 賞 講 演 ( 北 海 道 地 区 選 出 演 題 )
http://www.ike-dyn.ritsumei.ac.jp/ hyoo/wave.html 1 1, 5 3 1.1 1..................................... 3 1.2 5.1................................... 4 1.3.......................... 5 1.4 5.2, 5.3....................
家庭系パソコンの回収再資源化にかかる論点
1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
08サーベイ部会報告書v1117
CRBSI20012003 CAUTI20042005 2006 VAP VAP CRBSICAUTI X 2006 pilot study 2007 2008 VAP VAP VAP VAP VAP ICN VAP VAP VAP VAP VAP. VAP 2006 VAP 8 2007 2007 42 VAP 2007 2007 VAP 9 2004 NNIS 2007 2008. VAP 2007
PowerPoint プレゼンテーション
40 6 Fischer 2 McNemar 2 No Yes No Yes Mann Whitney s U Wilcoxon 1 Kruskal Wallis 2 Friedman No Yes 2 Yes No Yes Bonferroni ANOVA No Scheffe Yes Student s T No Paired T Welch s T 40 6 Fischer 2 McNemar
物理化学I-第12回(13).ppt
I- 12-1 11 11.1 2Mg(s) + O 2 (g) 2MgO(s) [Mg 2+ O 2 ] Zn(s) + Cu 2+ (aq) Zn 2+ (aq) + Cu(s) - 2Mg(s) 2Mg 2+ (s) + 4e +) O 2 (g) + 4e 2O 2 (s) 2Mg(s) + O 2 (g) 2MgO(s) Zn(s) Zn 2+ (aq) + 2e +) Cu 2+ (aq)
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
1,000 700-1 -
23 9 () - 0 - 1,000 700-1 - 2 3 ( 16:0017:00 ( 8:15 8:30 10:3010:50 8:00 8:10 8:10 9:30 11:0011:20 11:3015:30 16:0016:40 16:0016:10 16:50 21:00 4:00 4:006:00 6:00 6:1511:00 11:3012:00 12:3014:30 (1) ()
brother.\..2.ai
2004.3 95 pc 2 5 6 7 8 Q SC-370pc 9 HG-2614977766611312 HG-2514977766611329 HG-2414977766611336 HG-2314977766611343 HG-2214977766611350 HG-2114977766611367 TZ-FX2514977766621236 TZ-FX2414977766621229
2
1 2 3 4 5 6 ( ) 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 6+ 6-5 2 6-5- 6-5+ 5-5- 5- 22 6+ 6-6+ 6-6- S-P time 10 5 2 23 S-P time 5 2 5 2 ( ) 5 2 24 25 26 1 27 28 29 30 95 31 ( 8 2 ) http://www.kishou.go.jp/know/shindo/kaisetsu.html
ダイアライザー性能評価表
メーカー 品名 膜面積 膜素材 内径 膜厚 充填量 滅菌法 Dry (μm) (ml) Wet 旭化成クラレ APS-08SA 0.8 PS 185 45 48 γ W メディカル APS-11SA 1.1 PS 185 45 59 γ W APS-13SA 1.3 PS 185 45 71 γ W APS-15SA 1.5 PS 185 45 82 γ W APS-18SA 1.8 PS 185
Donald Carl J. Choi, β ( )
:: α β γ 200612296 20 10 17 1 3 2 α 3 2.1................................... 3 2.2................................... 4 2.3....................................... 6 2.4.......................................
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
untitled
DiBartola SP DiBartola SP 1987 Elliott Elliott J 1998 Elliott J 2000 Elliott J 2003 Part 1 24 0.75 70 1.3 1.3 2.0 1/2 2 6 1/2 22 18 Part 2003 Dr Chew 1 2 2 3 Part Cre Cre 1 Part Cre 2% 0.1ml/kg 0.3ml/kg
42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =
![42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =](/thumbs/73/68712188.jpg "42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =")
3 3.1 3.1.1 kg m s J = kg m 2 s 2 MeV MeV [1] 1MeV=1 6 ev = 1.62 176 462 (63) 1 13 J (3.1) [1] 1MeV/c 2 =1.782 661 731 (7) 1 3 kg (3.2) c =1 MeV (atomic mass unit) 12 C u = 1 12 M(12 C) (3.3) 41 42 3 u
エディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
A(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6
1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67
1 1 2 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 10. 11 1 12 1 13 2 13 3 8 13 4 14 5 14 6 14 7 15 8 15 1 17 2 22 3 24 4 24 1 33 2 42 1 49 2 50 3 50 4 56 1 60 2 88 3 93 1 95 2 96 1 98 2 100 1 100 2 104 3 105 4 105
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
JAJP
Agilent 7500ce ORS ICP-MS Glenn Woods Agilent Technologies Ltd. 5500 Lakeside, Cheadle Royal Business Park Stockport UK Agilent 7500ce ICP-MS 5 7500ce (ORS) 1 ORS 7500ce ORS ICP-MS ( ) 7500 ICP-MS (27.12
C-1 210C f f f f f f f f f f f f f f f f f f f f r f f f f f f f f f f f f f R R
4 5 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 7 b b ï φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ ù û û Æ φ ñ ó ò ô ö õ φφ! b ü ú ù û ü ß μ f f f f f f f f f f b b b z x c n 9 f φ φ φ φ φ φ
2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
現代物理化学 1-1(4)16.ppt
(pdf) pdf pdf http://www1.doshisha.ac.jp/~bukka/lecture/index.html http://www.doshisha.ac.jp/ Duet -1-1-1 2-a. 1-1-2 EU E = K E + P E + U ΔE K E = 0P E ΔE = ΔU U U = εn ΔU ΔU = Q + W, du = d 'Q + d 'W
web総合カタログ_ブック.indb
SUTURE PRODUCT CATALOG P.3 P.4 /Lot. No P.5 P.6 P.7 P.8 P.8 P.9 P.10 V-Loc V-Loc90 P.15 V-Loc180 P.17 V-LocPBT P.19 P.23 P.24 P.43 P.49 P.50 P.50 P.51 P.51 P.53 P.54 / P.55 P.27 P.30 P.30 P.31 P.31 P.32
さくらの個別指導 ( さくら教育研究所 ) A 2 2 Q ABC 2 1 BC AB, AC AB, BC AC 1 B BC AB = QR PQ = 1 2 AC AB = PR 3 PQ = 2 BC AC = QR PR = 1
... 0 60 Q,, = QR PQ = = PR PQ = = QR PR = P 0 0 R 5 6 θ r xy r y y r, x r, y x θ x θ θ (sine) (cosine) (tangent) sin θ, cos θ, tan θ. θ sin θ = = 5 cos θ = = 4 5 tan θ = = 4 θ 5 4 sin θ = y r cos θ =
油圧1.indd
4 2 ff f f f f f f f f f f f f ff ff ff r f ff ff ff ff ff ff R R 6 7 φφ φφ φφ φ φ φφ φφφφφφφφ φφφφ φφφφ φφ! φ f f f f f f f f f f 9 f φ φ φ φ φ φ φ φ φφ φφ φ φ φ φ SD f f f KK MM S SL VD W Y KK MM S SL
Taro9-医薬品目次２０１２－１.PDF
5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20
0.5mg (mg 2mg 3mg 50mg 00mg 4mg mg 0.5mg/g 0.5mg/g mg/g 2mg/g mg mg 00mg 5mg 0mg 0mg 0mg 65mg/g 5mg L- 200mg 4mEq/g 2.5mEq 5mEq 50mg 00mg 05mg 25mg 00
042007 6 4 2 2 7 4 283 2 0 7 337 3 4 9 84 3 0 5 355 4 4 5 82 4 7 5 249 5 3 3 5 4 22 75 2 0 6 3 7 3 7 9 4 5 4 76 4 0 6 5 5 2 5 7 22 2 3 0 9 9 790 6 7 2 0.5mg (mg 2mg 3mg 50mg 00mg 4mg mg 0.5mg/g 0.5mg/g
c 2009 i
I 2009 c 2009 i 0 1 0.0................................... 1 0.1.............................. 3 0.2.............................. 5 1 7 1.1................................. 7 1.2..............................
untitled
2 5 1 5 5.1 5.2 5.3 5.4 5.1 5.3 6 6.1 6.2 2 6.3 F 6.4 2 6.5 6.6 2 2 6.1 6.4 2 6.2 2 6.3 F 6.5 6.6 2 6.1 6.1 1 5 X N 2 /n Z X - / / n Z N 0 1 P -z /2 Z z /2 1- z P Z z = P X-z /2 / n X+ z /2 / n 100 % X-z
/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
P MB-Z.indd
エアシリンダ ø, ø, ø, ø, ø, ø 質量 New 16%削減 1.69kg RoHS ø-ストローク CJ1 CJP 従来品 2.01kg CM3 ロッドカバー ヘッドカバー 形状変更により質量削減 CG3 1 CS1 CS2 D- -X 技術 資料 383 øøøøøø MD D -Z- N V -M9W N 2 V 1 V1 W2 D2 T W 2 D2 N2 C1 G L V1 N
chap9.dvi
9 AR (i) (ii) MA (iii) (iv) (v) 9.1 2 1 AR 1 9.1.1 S S y j = (α i + β i j) D ij + η j, η j = ρ S η j S + ε j (j =1,,T) (1) i=1 {ε j } i.i.d(,σ 2 ) η j (j ) D ij j i S 1 S =1 D ij =1 S>1 S =4 (1) y j =
?
240-8501 79-2 Email: nakamoto@ynu.ac.jp 1 3 1.1...................................... 3 1.2?................................. 6 1.3..................................... 8 1.4.......................................
8 300 mm 2.50 m/s L/s ( ) 1.13 kg/m MPa 240 C 5.00mm 120 kpa ( ) kg/s c p = 1.02kJ/kgK, R = 287J/kgK kPa, 17.0 C 118 C 870m 3 R = 287J
26 1 22 10 1 2 3 4 5 6 30.0 cm 1.59 kg 110kPa, 42.1 C, 18.0m/s 107kPa c p =1.02kJ/kgK 278J/kgK 30.0 C, 250kPa (c p = 1.02kJ/kgK, R = 287J/kgK) 18.0 C m/s 16.9 C 320kPa 270 m/s C c p = 1.02kJ/kgK, R = 292J/kgK
,,., (,, SiO 2, Si-N, ),,,,,.,.,,, (Schottky). [ ].,..,.,., 1 m µm 10., 10 5, [ ] (6N-103)..,.,. [ ] 1. (,, ) :,.,,.., (HF),.
![,,., (,, SiO 2, Si-N, ),,,,,.,.,,, (Schottky). [ ].,..,.,., 1 m µm 10., 10 5, [ ] (6N-103)..,.,. [ ] 1. (,, ) :,.,,.., (HF),.](/thumbs/102/154256451.jpg ",,., (,, SiO 2, Si-N, ),,,,,.,.,,, (Schottky). [ ].,..,.,., 1 m µm 10., 10 5, [ ] (6N-103)..,.,. [ ] 1. (,, ) :,.,,.., (HF),.")
17 2 2.1,,., (,, SiO 2, Si-N, ),,,,,.,.,,, (Schottky). [ ].,..,.,., 1 m 3 0.1 µm 10., 10 5, 10 7. [ ] (6N-103)..,.,. [ ] 1. (,, ) :,.,,.., (HF),. 18 2,,.,,. 2.,,,.,,. 2.1. 19 2.1.1 1. 1, (Schottky),,,.
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 版が発効します 原文及び詳細はCPCホームページのCPC Revision
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 2019.08 版が発効します 原文及び詳細はCPCホームページのCPC Revisions(CPCの改訂 ) をご覧ください https://www.cooperativepatentclassification.org/cpcrevisions/noticeofchanges.html
untitled
, Kaoru ARIYAMA 10 17N, Na, Mg,Al,Si,P,S,Cl,K,Ca,Fe,Cu,Zn,Se,Br,Rb Sr 14r2 0.9617 Tricholoma matsutake,,, JAS ICP-OESICP-MS 2ICP-OES ICP-MS,, Tricholoma matsutake -24- 1 7 2006 70 13 8 5 2,, 2007,, 10
(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
熊本県数学問題正解
00 y O x Typed by L A TEX ε ( ) (00 ) 5 4 4 ( ) http://www.ocn.ne.jp/ oboetene/plan/. ( ) (009 ) ( ).. http://www.ocn.ne.jp/ oboetene/plan/eng.html 8 i i..................................... ( )0... (
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
4 1 Ampère 4 2 Ampere 31
4. 2 2 Coulomb 2 2 2 ( ) electricity 2 30 4 1 Ampère 4 2 Ampere 31 NS 2 Fleming 4 3 B I r 4 1 0 1.257 10-2 Gm/A µ 0I B = 2πr 4 1 32 4 4 A A A A 4 4 10 9 1 2 12 13 14 4 1 16 4 1 CH 2 =CH 2 28.0313 28 2
28 2 16 学 説 試 験 問 題 (A) 80 2 81 81 のうち を 横 線 で 81 とマークすれば 良 い HB 良 い 例 悪 い 例 1 a b c d e 2 a b c d e 3 a A b c d e 4 a b c d e 5 a b c d e 6 a b c d e T 7 a b c d e 嗉 8 9 a b c d e 10 a b c % d e B 11
I
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
2011de.dvi
211 ( 4 2 1. 3 1.1............................... 3 1.2 1- -......................... 13 1.3 2-1 -................... 19 1.4 3- -......................... 29 2. 37 2.1................................ 37
I II
I II I I 8 I I 5 I 5 9 I 6 6 I 7 7 I 8 87 I 9 96 I 7 I 8 I 9 I 7 I 95 I 5 I 6 II 7 6 II 8 II 9 59 II 67 II 76 II II 9 II 8 II 5 8 II 6 58 II 7 6 II 8 8 I.., < b, b, c, k, m. k + m + c + c b + k + m log
OABC OA OC 4, OB, AOB BOC COA 60 OA a OB b OC c () AB AC () ABC D OD ABC OD OA + p AB + q AC p q () OABC 4 f(x) + x ( ), () y f(x) P l 4 () y f(x) l P
4 ( ) ( ) ( ) ( ) 4 5 5 II III A B (0 ) 4, 6, 7 II III A B (0 ) ( ),, 6, 8, 9 II III A B (0 ) ( [ ] ) 5, 0, II A B (90 ) log x x () (a) y x + x (b) y sin (x + ) () (a) (b) (c) (d) 0 e π 0 x x x + dx e
6 2 T γ T B (6.4) (6.1) [( d nm + 3 ] 2 nt B )a 3 + nt B da 3 = 0 (6.9) na 3 = T B V 3/2 = T B V γ 1 = const. or T B a 2 = const. (6.10) H 2 = 8π kc2
![6 2 T γ T B (6.4) (6.1) [( d nm + 3 ] 2 nt B )a 3 + nt B da 3 = 0 (6.9) na 3 = T B V 3/2 = T B V γ 1 = const. or T B a 2 = const. (6.10) H 2 = 8π kc2](/thumbs/92/109118076.jpg "6 2 T γ T B (6.4) (6.1) [( d nm + 3 ] 2 nt B )a 3 + nt B da 3 = 0 (6.9) na 3 = T B V 3/2 = T B V γ 1 = const. or T B a 2 = const. (6.10) H 2 = 8π kc2")
1 6 6.1 (??) (P = ρ rad /3) ρ rad T 4 d(ρv ) + PdV = 0 (6.1) dρ rad ρ rad + 4 da a = 0 (6.2) dt T + da a = 0 T 1 a (6.3) ( ) n ρ m = n (m + 12 ) m v2 = n (m + 32 ) T, P = nt (6.4) (6.1) d [(nm + 32 ] )a
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
Note.tex 2008/09/19( )
1 20 9 19 2 1 5 1.1........................ 5 1.2............................. 8 2 9 2.1............................. 9 2.2.............................. 10 3 13 3.1.............................. 13 3.2..................................
AD-5423_2
/ 2 /2.7 /CTD 8 8 II II 1 2 6 mg/ 6 mg/ HIV C 80 mmhg 3 1 3 80 mmhg 31 / 2 /2.7 /CTD 8 8 II II 1 2 3 23 32 / 2 /2.7 /CTD 2.7.3.3.1-28 123 2.7.3.3.1-2 8 1 2 3 2.7.3.3.1-3 2.7.3.3.1-48 2.7.3.3.1-5 40 5 7
K 1 mk(
R&D ATN K 1 mk(0.01 0.05 = ( ) (ITS-90)-59.3467 961.78 (T.J.Seebeck) A(+ T 1 I T 0 B - T 1 T 0 E (Thermoelectromotive force) AB =d E(AB) /dt=a+bt----------------- E(AB) T1 = = + + E( AB) α AB a b ( T0
A (1) = 4 A( 1, 4) 1 A 4 () = tan A(0, 0) π A π
4 4.1 4.1.1 A = f() = f() = a f (a) = f() (a, f(a)) = f() (a, f(a)) f(a) = f 0 (a)( a) 4.1 (4, ) = f() = f () = 1 = f (4) = 1 4 4 (4, ) = 1 ( 4) 4 = 1 4 + 1 17 18 4 4.1 A (1) = 4 A( 1, 4) 1 A 4 () = tan
橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
1. 2 P 2 (x, y) 2 x y (0, 0) R 2 = {(x, y) x, y R} x, y R P = (x, y) O = (0, 0) OP ( ) OP x x, y y ( ) x v = y ( ) x 2 1 v = P = (x, y) y ( x y ) 2 (x
. P (, (0, 0 R {(,, R}, R P (, O (0, 0 OP OP, v v P (, ( (, (, { R, R} v (, (, (,, z 3 w z R 3,, z R z n R n.,..., n R n n w, t w ( z z Ke Words:. A P 3 0 B P 0 a. A P b B P 3. A π/90 B a + b c π/ 3. +